Asano M - Search Results

1

Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients.

Kondo S, Asano M, Matsuo K, Ohmori I, Suzuki H. Kondo S, et al. Among authors: asano m. Biochim Biophys Acta. 1994 Mar 31;1221(2):211-4. doi: 10.1016/0167-4889(94)90016-7. Biochim Biophys Acta. 1994. PMID: 8148401

2

Increase in serum vascular endothelial growth factor levels during altitude training.

Asano M, Kaneoka K, Nomura T, Asano K, Sone H, Tsurumaru K, Yamashita K, Matsuo K, Suzuki H, Okuda Y. Asano M, et al. Among authors: asano k. Acta Physiol Scand. 1998 Apr;162(4):455-9. doi: 10.1046/j.1365-201X.1998.0318e.x. Acta Physiol Scand. 1998. PMID: 9597111

3

Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor.

Asano M, Yukita A, Suzuki H. Asano M, et al. Jpn J Cancer Res. 1999 Jan;90(1):93-100. doi: 10.1111/j.1349-7006.1999.tb00671.x. Jpn J Cancer Res. 1999. PMID: 10076571 Free PMC article.

4

Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody.

Kondo S, Asano M, Suzuki H. Kondo S, et al. Among authors: asano m. Biochem Biophys Res Commun. 1993 Aug 16;194(3):1234-41. doi: 10.1006/bbrc.1993.1955. Biochem Biophys Res Commun. 1993. PMID: 7688963

5

Isolation and characterization of neutralizing monoclonal antibodies to human vascular endothelial growth factor/vascular permeability factor121 (VEGF/VPF121).

Asano M, Yukita A, Matsumoto T, Matsuo K, Kondo S, Suzuki H. Asano M, et al. Hybridoma. 1995 Oct;14(5):475-80. doi: 10.1089/hyb.1995.14.475. Hybridoma. 1995. PMID: 8575796

6

Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121.

Asano M, Yukita A, Matsumoto T, Kondo S, Suzuki H. Asano M, et al. Cancer Res. 1995 Nov 15;55(22):5296-301. Cancer Res. 1995. PMID: 7585591

7

An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo.

Asano M, Yukita A, Matsumoto T, Hanatani M, Suzuki H. Asano M, et al. Hybridoma. 1998 Apr;17(2):185-90. doi: 10.1089/hyb.1998.17.185. Hybridoma. 1998. PMID: 9627059

8

Anti-tumor and anti-metastatic effects of human-vascular-endothelial-growth-factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice.

Kanai T, Konno H, Tanaka T, Baba M, Matsumoto K, Nakamura S, Yukita A, Asano M, Suzuki H, Baba S. Kanai T, et al. Among authors: asano m. Int J Cancer. 1998 Sep 11;77(6):933-6. doi: 10.1002/(sici)1097-0215(19980911)77:6<933::aid-ijc23>3.0.co;2-0. Int J Cancer. 1998. PMID: 9714067 Free article.

9

Hypoxia and endothelin-1 induce VEGF production in human vascular smooth muscle cells.

Okuda Y, Tsurumaru K, Suzuki S, Miyauchi T, Asano M, Hong Y, Sone H, Fujita R, Mizutani M, Kawakami Y, Nakajima T, Soma M, Matsuo K, Suzuki H, Yamashita K. Okuda Y, et al. Among authors: asano m. Life Sci. 1998;63(6):477-84. doi: 10.1016/s0024-3205(98)00296-3. Life Sci. 1998. PMID: 9718071

10

Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo.

Yukita A, Asano M, Okamoto T, Mizutani S, Suzuki H. Yukita A, et al. Among authors: asano m. Anticancer Res. 2000 Jan-Feb;20(1A):155-60. Anticancer Res. 2000. PMID: 10769648

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,632 results

Search Page